US FDA grants fast track designation to CRISPR & Vertex\'s CTX001 to treat sickle cell disease

US FDA grants fast track designation to CRISPR & Vertex's CTX001 to treat sickle cell disease

CRISPR Therapeutics and Vertex Pharmaceuticals Incorporated announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation for CTX001 for the treatment of sickle cell

More From BioPortfolio on "US FDA grants fast track designation to CRISPR & Vertex's CTX001 to treat sickle cell disease"